Wilson Sonsini Goodrich & Rosati advised Acumen Pharmaceuticals on the deal. Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target...
Acumen Pharmaceuticals’ $160 Million IPO
Cullgen Inc.’s $50 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Cullgen Inc. on the deal. Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™...